George M. Milne Jr - Dec 31, 2022 Form 5 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Director
Signature
/s/ Joshua B. Cohen, as Attorney-in-Fact
Stock symbol
AMLX
Transactions as of
Dec 31, 2022
Transactions value $
$0
Form type
5
Date filed
2/14/2023, 03:35 PM
Previous filing
Jun 10, 2022
Next filing
Mar 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Conversion of derivative security +689K +311.4% 911K Jan 6, 2022 Direct F1
transaction AMLX Common Stock Gift $0 -13.8K -1.52% $0.00 897K Dec 29, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Series A Preferred Stock Conversion of derivative security $0 -262K -100% $0.00* 0 Jan 6, 2022 Common Stock 262K Direct F1
transaction AMLX Series B Preferred Stock Conversion of derivative security $0 -384K -100% $0.00* 0 Jan 6, 2022 Common Stock 384K Direct F1
transaction AMLX Series C-1 Preferred Stock Conversion of derivative security $0 -19.5K -100% $0.00* 0 Jan 6, 2022 Common Stock 19.5K Direct F1
transaction AMLX Series C-2 Preferred Stock Conversion of derivative security $0 -23.2K -100% $0.00* 0 Jan 6, 2022 Common Stock 23.2K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.